Aufpassen auf VION Parma! ASCO Meeting am 6.5.

WKN 902 972
Innerhalb der vergangenen 12 Monate hat sich der Kurs von VION PHARMA glatt verzehnfacht! Anfang April 2003 bekam man die Aktie des Unternehmens zu Kursen um USD 0.30 noch hinterhergeworfen, was sich mit den präsentierten Forschungsdaten beim letztjährigen ASCO-Meeting dann schlagartig änderte.



Im Rahmen des wichtigsten Krebskongresses berichtete VION PHARMA von erstaunlich guten Resultaten von Triapine gegen bei der Behandlung verschiedener Krebsarten und von Cloretazine gegen Leukämie, worauf der Markt mit einer Kursexplosion reagierte.
Für Cloretazine hat das Unternehmen kürzlich von der FDA den Fast Track-Status erhalten, der dem Präparat ein beschleunigtes Zulassungsverfahren zusichert. So kann VION PHARMA bereits Studienergebnisse bei der Gesundheitsbehörde einreichen, noch bevor abschließende Phase III-Resultate vorliegen. Gut möglich, dass die Präsentation von VION PHARMA auch beim diesjährigen ASCO-Meeting mit einem weiteren Paukenschlag endet. Die institutionellen Anleger scheinen jedenfalls überzeugt, dass noch einiges von der Biotech-Schmiede zu erwarten ist. Erst vergangenen Monat rissen erstrangige Investoren dem Unternehmen nicht nur neue Aktien zu laufenden Kursen, sondern gleich noch Optionen für den Bezug von Aktien zum Kurs von USD 3.25 aus den Händen, was zum damaligen Zeitpunkt einer Prämie von immerhin rund 30% entsprach!  

letzte ASCO Jahrestagung Ende Mai 2003                

       
     
VION PHARMACEUTICALS, INC.
                 (A Development Stage Company)
               CONDENSED STATEMENTS OF OPERATIONS
                     (Unaudited)
                                       Three Months Ended
                                             March 31,
(In thousands, except per share data)     2004          2003
Revenues:
Contract research grants               $  63         $ 66
Research and laboratory support fees      24            3
Technology license fees                    9           --
  Total revenues                          96           69
Operating expenses:
Clinical trials                        1,805          876
Other research and development           957          969
  Total research and development       2,762        1,845
General and administrative               617          702
  Total operating expenses             3,379        2,547
Loss from operations                    (3,283)      (2,478)
Interest income                           91           31
Other expense                           (32)           --
Loss before income taxes                (3,224)      (2,447)
Income tax provision (benefit)            34         (22)
Net loss                                (3,258)      (2,425)
Basic and diluted loss per share         (0.07)       (0.08)
Weighted-average number of
 shares of common stock outstanding      47,309       28,927



kompletter Quartalsbericht unter
http://biz.yahoo.com/e/040514/vion10-q.html

Thread ist kaum drin und schon ein grüner :)
NETT!!!

NEW HAVEN, Conn., May 10 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION - News)

announced today that it would be making a corporate presentation at the Rodman & Renshaw Techvest Global Healthcare Conference on Wednesday, May 12, 2004 at 12:20 p.m. BST. The conference is taking place at the Claridge's Hotel in London, England and the presentation will be in the Drawing Room.
The slides from the presentation will be posted to Vion's website, www.vionpharm.com, at 7:20 a.m. EDT on May 12, 2004.
Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. Vion has two agents in Phase II clinical trials: Triapine®, a potent inhibitor of a key step in DNA synthesis and CLORETAZINE(TM) (VNP40101M), a unique sulfonylhydrazinealkylating agent. Vion is also developing and has an option to license several heterocyclic hydrazones which have demonstrated potent anti-tumor activity in preclinical studies. Additional agents in preclinical studies include:
KS119, a hypoxia-selective compound from the sulfonyl hydrazine class and TAPET®, a modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit
the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's ability to secure external sources of funding to continue its operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, its dependence on regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Vion's Annual Report on Form 10-K/A for the year ended December 31, 2003. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.  

Dies ist meine persönliche Meinung.
Vion Pharma ist ein BIOTEC-Wert.
Es ist eine allgemein bekannte Tatsache, dass biotec Aktien z.T. sehr volatil sind und damit für den Anleger ein gewisses RISIKO darstellen.
Wer das nicht weiß, sollte es sich merken!
Schönen Gruß,
vom Nussriegel

Vion Pharmaceuticals Kaufempfehlung

Die Experten vom Börsenbrief "Global Biotech Investing" empfehlen den Titel von Vion Pharmaceuticals (ISIN US9276241067/ WKN 902972) zum Kauf. Innerhalb der letzten 12 Monate habe sich der Kurs des Pharmaunternehmens glatt verzehnfacht. Zurückzuführen sei dies zum Großteil auf die publizierten Forschungsdaten beim letztjährigen ASCO-Meeting. Im Rahmen des bedeutenden Krebskongresses habe das Unternehmen von erstaunlich guten Resultaten beim Präparat Triapine berichtet. Der Aktienkurs sei daraufhin schlagartig nach oben gegangen. Nachdem er bei 4 USD leicht überhitzt sei, habe man erste Teilgewinnmitnahmen empfohlen. Nach der erwarteten Abkühlung sollten nun aber wieder Positionsaufstockungen vorgenommen werden. Vion habe nämlich für das Präparat Cloretazine von der FDA den Fast-Track-Status erhalten, welcher dem Medikament ein beschleunigtes Zulassungsverfahren zusichere. Nach Meinung der Wertpaperexperten sei es gut möglich, dass die Präsentation von Vion auf dem diesjährigen ASCO-Meeting wieder erfolgreich laufen sollte. Institutionelle Anleger würden jedenfalls fest damit rechnen, dass von diesem Pharmaunternehmen noch einiges zu erwarten sei. Die Experten vom "Global Biotech Investing" raten den Anlegern die Aktie von Vion Pharmaceuticals zu kaufen.
Quelle: AKTIENCHECK.DE, 30.4.04

aber jetzt ist wirklich mal wer anders dran,
seine Meinung daszu zu äußern.
Gruß und good trades,
Nussriegel

 VION    
VION PHARMACEUTICALS INC  
  4.170  
+0.020  +0.48%  


Daily Commentary  

    WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 5/24/2004 (3) days ago, when the stock price was 4.180. Since then the stock fell -0.24% .  

Today the stock closed higher, close to its low (sign of weakness) with a higher high and a higher low. The volume is extremely low. The security price is trending down.



Click here to get a full trend analysis of this stock   Candlestick Analysis  
           

Today’s Candlestick Patterns:
Spinning Top


Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bears and a potential change or interruption in the current trend!





Gruß

GS

Mit welchem tool ist die Chartanalyse gemacht?
Habe schon letzte Wochen gekauft, weil ich angenomen habe, dass der Chart früher dreht.
Wenn ich rechtzeitig die Vivacon-Kohle freihabe, kaufe ich evtl. noch mal günstig nach.
In Anbetracht dessen, was der Wert seit Januar gemacht hat (300%) und dem, was vom ASCO-Meeting zu erwarten ist, sehe ich gute Chancen, dass da nochmal was geht.
Richte mich auch viel nach Charts, aber man sollte die News ja nicht ganz außer acht lassen.
Good trades,
NR  

CLORETAZINE(TM) (VNP40101M) is a novel DNA-damaging alkylating agent with broad spectrum anti-tumor activity in preclinical studies. Two Phase I trials in solid tumors, which have completed accrual, have investigated the safety profile, maximum tolerated dose and schedule for Phase II trials, as well as the pharmacokinetic parameters (blood levels) of the agent. Vion plans additional Phase II trials in other solid tumors, and has an ongoing clinical development program in hematologic malignancies.

Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. Vion has two agents in Phase II clinical trials: Triapine®, a potent inhibitor of a key step in DNA synthesis and CLORETAZINE(TM) (VNP40101M), a unique sulfonylhydrazine alkylating agent. Vion is also developing and has an option to license several heterocyclic hydrazones which have demonstrated potent anti-tumor activity in preclinical studies. Additional agents in preclinical studies include: KS119, a hypoxia-selective compound from the sulfonylhydrazine class and TAPET®, a modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com .

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's ability to secure external sources of funding to continue its operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, its dependence on regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Vion's Annual Report on Form 10-K/A for the year ended December 31, 2003. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Abstracts search for Vion returned 7 result(s).
1. A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer.
Home > Meetings & Education > Abstracts >
Meeting: 2004 ASCO Annual Meeting   Abstract No: 2060   First Author: J. Murren
Category: Pharmacology/pharmacokinetics


2. Phase I study of VNP40101M (101M) and AraC in patients (pts) with refractory leukemia.
Home > Meetings & Education > Abstracts >
Meeting: 2004 ASCO Annual Meeting   Abstract No: 6617   First Author: F. J. Giles
Category: Leukemia

leider bisher keine Explosion wie letztes Jahr
naja, warten wir mal ab, was passiert
Grüße,
Nussriegel

und hier noch ne news:

Associated Press
Vion: Most Patients Tolerate Cancer Drug
Monday June 7, 12:27 pm ET  
Vion Says Data From Early-Stage Trial Shows Anti-Cancer Drug Is Well-Tolerated in Most Patients


NEW HAVEN, Conn. (AP) -- Cancer drug developer Vion Pharmaceuticals Inc. reported Monday that data from an early-stage trial showed its Cloretazine anti-cancer drug was well-tolerated in most patients.


Vion said the Phase I trial studied the effects of a weekly intravenous dose of Cloretazine administered for three consecutive weeks in four-week cycles, or as tolerated. Data was presented on 23 patients with advanced or metastatic solid tumors or lymphomas, 22 of whom had previously undergone chemotherapy.

Data showed that Cloretazine was well-tolerated in most patients and produced minimal non-hematologic toxicity. The most common adverse events were reductions in blood counts. The frequency with which cycles could be repeated depended on the dose, and two schedules were determined to be appropriate for Phase II trials: a higher weekly dose for three weeks out of every six weeks, or a lower weekly dose for three weeks out of every four weeks.

The company said evidence of anti-tumor effect, consisting of stabilized disease for several cycles or tumor shrinkage, was observed in three patients.

Dr. Mario Sznol, vice president of clinical affairs, stated, "The preclinical data suggested that a multiple-dose schedule may be preferable for anti-tumor activity. We hope to commence Phase II trials of the weekly schedule in one or more solid tumors or lymphoma in the future."

Vion has conducted one other Phase I trial of Cloretazine in solid tumors, and two Phase I trials in leukemia.

finance.yahoo.com/q/it?s=VION

NET SHARE PURCHASE ACTIVITY

Insider Purchases - Last 6 Months
 Shares Trans
Purchases N/A N/A
Sales 2,145,000 29
Net Shares Purchased
(Sold) (2,145,000) 29
Total Insider Shares Held N/A N/A  
% Net Shares Purchased
(Sold) (69.2 N/A  


Net Institutional Purchases - Prior Qtr to Latest Qtr
 Shares
Net Shares Purchased (Sold) 15,038,000
% Change in Institutional Shares Held 40.9%

Data provided by Reuters

 
 
Stock Picks based

on Insider Trading.